001540 — Ahn-Gook Pharmaceutical Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩86bn
- KR₩68bn
- KR₩234bn
- 57
- 67
- 19
- 44
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 79,350 | 48,592 | 46,209 | 36,092 | 35,446 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 47,288 | 37,893 | 44,159 | 55,597 | 62,753 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 152,139 | 111,432 | 116,285 | 122,010 | 135,416 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 48,036 | 70,554 | 70,911 | 70,771 | 73,036 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 217,957 | 201,702 | 211,796 | 223,912 | 238,598 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 56,282 | 44,678 | 52,212 | 61,498 | 78,242 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 69,710 | 57,603 | 66,535 | 69,115 | 86,511 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 148,247 | 144,098 | 145,261 | 154,798 | 152,086 |
Total Liabilities & Shareholders' Equity | 217,957 | 201,702 | 211,796 | 223,912 | 238,598 |
Total Common Shares Outstanding |